Researches with the Ovarian Tumor Tissue Analyses Consortium analyzed the CD8+ (cytotoxic T-cell) content of tumors from 5,500 patients and compared them with clinical outcome. The analysis was large enough to allow for comparison by histologic subtype – endometrioid, clear cell, mucinous, and low-grade serous ovarian cancer, as well as high-grade serous ovarian cancer. Included in the sample were 3,200 high grade serous ovarian cancers. Continue reading
Tag Archives: CD8+
Priming cancer for immunotherapy
Augmenting the responses to checkpoint inhibitors, which remove the “breaks” from the immune response, is a very popular area of research. The general concept is to turn immunologically cold tumors hot. For example, triple negative breast cancer (TNBC) is considered an immunologically cold tumor – anti-PD(L)1 therapy has shown responses of just 5-10%. Continue reading
Neo-antigen vaccines extend progression-free survival in melanoma
Two companies – Biontech, RNA vaccine and Neon Therapeutics, peptide vaccine – reported very positive results of neo-antigen vaccines in patients with refractory metastatic melanoma. Continue reading
Peripheral white blood cell profiles may predict response to checkpoint blockade
While some patients enjoy excellent and durable responses to treatment with checkpoint inhibits, most do not, and some even hyper-progress. Selecting patients who will benefit most has been challenging. Continue reading
Argos’ Metastatic Renal Cell Carcinoma Study Passes Independent Data Safety Monitoring Committee Second Interim Analysis
An independent data monitoring committee (IDMC) has recommended the continuation of Argos’ pivotal phase 3 ADAPT clinical trial of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC) based on results of the committee’s second planned interim data analysis. The next planned interim analysis will be in 6 months. Continue reading
ImaginAB’s Minibodies for CD8+ T Cell Targeting – Select Optimal Immunotherapy Approaches
ImaginAB and Eli Lilly announced a pre-clinical collaboration to use ImaginAb’s immune imaging agent IAB22M2C to study new T-cell therapies cancer. Continue reading
Novel mutated antigens from Tumor Infiltrating Lymphocytes from long-term melanoma responders
Tumor Infiltrating Lymphocytes (TILs) are cytotoxic T-cells that are found in tumors. They serve to destroy cancer, or at least keep cancer at bay. Adoptive immunotherapy, Continue reading